Hikma receives FDA approval for Etomidate Injection

London, 9 March 2016 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (“ANDA”) for Etomidate Injection USP, 2mg/mL (10 mL and 20 mL single-dose vials) , has been approved by the U.S. Food and Drug Administration (“FDA”).